GSK: Over 20 yearsof commitmentto research anddevelopment in SLE
We strive to improve the understanding of how to:
Improve the control
of disease activity
Visit the GSK company page on the EULAR platform
to find out more!
©2020 GSK group of companies. All rights reserved.
PM-GBL-BEL-ADV T-200005 Date of preparation: May 2020
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcardin the Google Play or Apple App store. For Germany, adverse events should be reported to Paul-Ehrlich-Institut: www.pei.de or on +49 6103 77 0.Adverse events should also be reported to GlaxoSmithKline on +44 800 221 441 or, for Germany, to https://de.gsk.com, or on +49 800 122 33 55.If you are professionally active in a country other than Germany, adverse events should be reported to the appropriate health authority in your country.